TrialEuropean journal of neurology2021

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.

Sarah Harris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.